Advertisement

Follow us on Twitter @CR_AACR!

From the Current Issue

  • Tumor Biology and Immunology
    MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer
    Mengyu Xie, Hong Zheng, Ranjna Madan-Lala, Wenjie Dai, Nicholas T. Gimbrone, Zhihua Chen, Fumi Kinose, Sarah A. Blackstone, Keiran S.M. Smalley, W. Douglas Cress, Eric B. Haura, Uwe Rix and Amer A. Beg
    Cancer Res November 15 2019 79 (22) 5812-5825; DOI:10.1158/0008-5472.CAN-19-0698

    Lung cancer cells are rendered sensitive to MEK inhibitors by TNFα and IFNγ, providing strong mechanistic rationale for combining immunotherapeutics, such as checkpoint blockers, with MEK inhibitor therapy for lung cancer.

  • Molecular Cell Biology | AuthorChoice
    YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification
    Natsuki Hamanaka, Yoshito Nakanishi, Takakazu Mizuno, Kana Horiguchi-Takei, Nukinori Akiyama, Hiromi Tanimura, Masami Hasegawa, Yasuko Satoh, Yukako Tachibana, Toshihiko Fujii, Kiyoaki Sakata, Kiyomoto Ogasawara, Hirosato Ebiike, Hiroshi Koyano, Haruhiko Sato, Nobuya Ishii and Toshiyuki Mio
    Cancer Res November 15 2019 79 (22) 5734-5745; DOI:10.1158/0008-5472.CAN-18-3376

    These findings identify the SRC family kinase YES1 as a targetable oncogene in esophageal cancer and describe a new inhibitor for YES1 that has potential for clinical utility.

See the Table of Contents

Recent Reviews

OnlineFirst Articles

Load more
Advertisement

Back to top